Bionexus Gene Lab (BGLC) GlobeNewswire News Room·2025-03-05 16:00Core Insights - BioNexus Gene Lab Corp. (BGLC) has become the first Nasdaq-listed company to prioritize Ethereum (ETH) as a strategic treasury asset, aligning with Ethereum's inclusion in the US "Crypto Strategic Reserve" [1][2] - The company has released an Ethereum Strategy Whitepaper that outlines the rationale for this decision and Ethereum's significance as a financial infrastructure asset [2][4] Group 1: Board Approval and Strategic Direction - The Board of Directors has approved the new Ethereum-focused treasury strategy after extensive analysis, recognizing Ethereum as a strategic treasury management solution [3] - Wyoming's blockchain-friendly laws have influenced BGLC's strategic direction, providing a pro-business regulatory environment that supports blockchain innovation [3] Group 2: Ethereum Strategy Whitepaper - The Ethereum Strategy Whitepaper details Ethereum's institutional adoption, staking capabilities, and upcoming protocol upgrades, emphasizing its long-term value and corporate utility [2][4] - The whitepaper distinguishes Ethereum as a programmable financial platform, contrasting it with Bitcoin's store-of-value approach [4] Group 3: Future Commitments and Innovations - BGLC plans to explore Ethereum-based financial applications and innovative treasury management practices, while also assessing the impact of Wyoming's stablecoin issuance framework [5] - The company aims to enhance its financial resilience and attract forward-thinking investors by integrating Ethereum into its corporate treasury [8] Group 4: Ethereum's Financial Attributes - Ethereum is recognized for its institutional credibility, yield-generation capabilities through its Proof-of-Stake (PoS) system, and dominance in financial infrastructure, underpinning trillions of dollars in stablecoin transactions annually [6] - Upcoming upgrades, such as the major Pectra upgrade, are expected to enhance Ethereum's efficiency and scalability [6][7]